



#7/A
1-24-02

PATENT
Customer Number 22,852
Attorney Docket No. 8888.1129

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Jean-Francois DEDIEU et al.

Serial No.: 09/654,223

Filed: August 31, 2000

Group Art Unit: 1632

Examiner: D. Nguyen

RECEIVED
DEC 18 2002
TECH CENTER 1600/2900

For: RECOMBINANT ADENOVIRUSES FOR GENE THERAPY IN CANCERS

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

RESPONSE UNDER 37 C.F.R. § 1.111 TO PAPER NO. 5

In response to the Office Action dated July 17, 2002 (Paper No. 5), the period for response having been extended by a petition for extension of time and fee filed concurrently herewith, and pursuant to 37 C.F.R. § 1.173(d), please enter the following amendment:

IN THE SPECIFICATION:

Column 1, lines 4-5, first paragraph:

This application is a reissue application of U.S. Patent No. 5,837,531, which issued on November 17, 1998, from U.S. Application S.N. 08/646,246, which is a national phase application under 35 U.S.C. 371 of PCT/FR 94/01284, filed Nov. 07, 1994, which claims priority to FR 93 13766 filed on November 18, 1993.

AI
FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

12/17/2002 SSESHE1 00000016 09654223

01 FC:1202

90.00 0P

445008_1